These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 22860005)

  • 1. TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation.
    Casey OM; Fang L; Hynes PG; Abou-Kheir WG; Martin PL; Tillman HS; Petrovics G; Awwad HO; Ward Y; Lake R; Zhang L; Kelly K
    PLoS One; 2012; 7(7):e41668. PubMed ID: 22860005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the TMPRSS2-ERG gene fusion in prostate cancer.
    Tomlins SA; Laxman B; Varambally S; Cao X; Yu J; Helgeson BE; Cao Q; Prensner JR; Rubin MA; Shah RB; Mehra R; Chinnaiyan AM
    Neoplasia; 2008 Feb; 10(2):177-88. PubMed ID: 18283340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.
    Yang Y; Blee AM; Wang D; An J; Pan Y; Yan Y; Ma T; He Y; Dugdale J; Hou X; Zhang J; Weroha SJ; Zhu WG; Wang YA; DePinho RA; Xu W; Huang H
    Cancer Res; 2017 Dec; 77(23):6524-6537. PubMed ID: 28986382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.
    Mounir Z; Lin F; Lin VG; Korn JM; Yu Y; Valdez R; Aina OH; Buchwalter G; Jaffe AB; Korpal M; Zhu P; Brown M; Cardiff RD; Rocnik JL; Yang Y; Pagliarini R
    Oncogene; 2015 Jul; 34(29):3815-25. PubMed ID: 25263440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer.
    Zammarchi F; Boutsalis G; Cartegni L
    PLoS One; 2013; 8(3):e49721. PubMed ID: 23472063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
    Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
    Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.
    Cai C; Wang H; He HH; Chen S; He L; Ma F; Mucci L; Wang Q; Fiore C; Sowalsky AG; Loda M; Liu XS; Brown M; Balk SP; Yuan X
    J Clin Invest; 2013 Mar; 123(3):1109-22. PubMed ID: 23426182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear receptor ERRĪ± and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer.
    Xu Z; Wang Y; Xiao ZG; Zou C; Zhang X; Wang Z; Wu D; Yu S; Chan FL
    Oncogene; 2018 Nov; 37(48):6259-6274. PubMed ID: 30042415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
    Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
    Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
    Furusato B; Gao CL; Ravindranath L; Chen Y; Cullen J; McLeod DG; Dobi A; Srivastava S; Petrovics G; Sesterhenn IA
    Mod Pathol; 2008 Feb; 21(2):67-75. PubMed ID: 18065961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.
    King JC; Xu J; Wongvipat J; Hieronymus H; Carver BS; Leung DH; Taylor BS; Sander C; Cardiff RD; Couto SS; Gerald WL; Sawyers CL
    Nat Genet; 2009 May; 41(5):524-6. PubMed ID: 19396167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.
    Qu X; Randhawa G; Friedman C; O'Hara-Larrivee S; Kroeger K; Dumpit R; True L; Vakar-Lopez F; Porter C; Vessella R; Nelson P; Fang M
    Cancer Genet; 2013; 206(1-2):1-11. PubMed ID: 23352841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models.
    Raina K; Kant R; Prasad RR; Kandhari K; Tomar M; Mishra N; Kumar R; Fox JT; Sei S; Shoemaker RH; Chen Y; Maroni P; Agarwal C; Agarwal R
    Mol Carcinog; 2022 Jul; 61(7):717-734. PubMed ID: 35452553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
    Mehra R; Tomlins SA; Yu J; Cao X; Wang L; Menon A; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
    Cancer Res; 2008 May; 68(10):3584-90. PubMed ID: 18483239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions.
    Singareddy R; Semaan L; Conley-Lacomb MK; St John J; Powell K; Iyer M; Smith D; Heilbrun LK; Shi D; Sakr W; Cher ML; Chinni SR
    Mol Cancer Res; 2013 Nov; 11(11):1349-61. PubMed ID: 23918819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.
    Mertz KD; Setlur SR; Dhanasekaran SM; Demichelis F; Perner S; Tomlins S; Tchinda J; Laxman B; Vessella RL; Beroukhim R; Lee C; Chinnaiyan AM; Rubin MA
    Neoplasia; 2007 Mar; 9(3):200-6. PubMed ID: 17401460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer.
    Smit FP; Salagierski M; Jannink S; Schalken JA
    BJU Int; 2013 May; 111(5):836-42. PubMed ID: 23578236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.
    Cai C; Wang H; Xu Y; Chen S; Balk SP
    Cancer Res; 2009 Aug; 69(15):6027-32. PubMed ID: 19584279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of nonsteroidal anti-inflammatory drugs (aspirin and naproxen) on inflammation-associated proteomic profiles in mouse plasma and prostate during TMPRSS2-ERG (fusion)-driven prostate carcinogenesis.
    Prasad RR; Mishra N; Kant R; Fox JT; Shoemaker RH; Agarwal C; Raina K; Agarwal R
    Mol Carcinog; 2024 Jun; 63(6):1188-1204. PubMed ID: 38506376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.